Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
23 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
16 Apr 24
8-K
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
27 Mar 24
8-K
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
1 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Feb 24
8-K
Departure of Directors or Certain Officers
23 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Jan 24
8-K
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
11 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
22 Dec 23
8-K
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
7 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
1 Mar 24
FWP
Free writing prospectus
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
S-3
Shelf registration
9 Jun 23
S-8
Registration of securities for employees
26 Aug 22
424B4
Prospectus supplement with pricing info
22 Jun 22
S-8
Registration of securities for employees
7 Sep 21
S-3
Shelf registration
1 Jun 20
S-8
Registration of securities for employees
1 Apr 19
424B4
Prospectus supplement with pricing info
28 Mar 19
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Jan 24
DEFA14A
Additional proxy soliciting materials
4 Dec 23
DEF 14A
Definitive proxy
4 Dec 23
PRE 14A
Preliminary proxy
22 Nov 23
DEFA14A
Additional proxy soliciting materials
23 Mar 23
DEF 14A
Definitive proxy
23 Mar 23
DEFA14A
Additional proxy soliciting materials
29 Mar 22
DEF 14A
Definitive proxy
29 Mar 22
Other
EFFECT
Notice of effectiveness
16 Jun 23
CORRESP
Correspondence with SEC
13 Jun 23
UPLOAD
Letter from SEC
12 Jun 23
EFFECT
Notice of effectiveness
12 Jun 20
CORRESP
Correspondence with SEC
9 Jun 20
UPLOAD
Letter from SEC
9 Jun 20
CT ORDER
Confidential treatment order
28 Mar 19
EFFECT
Notice of effectiveness
28 Mar 19
CERT
Certification of approval for exchange listing
25 Mar 19
CORRESP
Correspondence with SEC
25 Mar 19
Ownership
4
J. JEFFERSON SMITH
22 Apr 24
4
Michael Amoroso
22 Apr 24
4
Dario Scimeca
22 Apr 24
4
John Alexander Kelly
22 Apr 24
SC 13G
Aquilo Capital Management, LLC
18 Mar 24
SC 13G
PERCEPTIVE ADVISORS LLC
14 Mar 24
SC 13G
JANUS HENDERSON GROUP PLC
11 Mar 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Capital World Investors
12 Feb 24
SC 13G
TANG CAPITAL PARTNERS LP
5 Feb 24